- Home
- AMSS vs LITS Comparison
AMSS vs LITS Comparison
Compare AMSS & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMSS | LITS |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 25.7M |
| IPO Year | 2026 | 2003 |
Fundamental Metrics
Financial Performance| Metric | AMSS | LITS |
|---|---|---|
| Price | $0.35 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 140.7K | ★ 930.1K |
| Earning Date | 08-14-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.71 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.69 |
| 52 Week High | $2.44 | $2.26 |
Technical Indicators
Market Signals| Indicator | AMSS | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 21.86 | 49.21 |
| Support Level | N/A | $1.06 |
| Resistance Level | $0.81 | $1.25 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 1.82 | 13.51 |
Price Performance
Historical ComparisonAbout AMSS AMASS Brands Inc. Common Stock
Amass Brands Inc is building a diversified premium beverage platform at the intersection of craft, wellness, and functionality. The company operates in the beverage industry, offering a portfolio that includes spirits, wine, and non-alcoholic products. The company distributes its brands in the United States through wholesale, on-premise, and direct-to-consumer channels. The company has two segments: Wine and Spirits. The majority of the company's revenue is derived from the Wine segment, which offers a portfolio of premium imported and domestic wine brands. Geographically, it operates predominantly in the USA.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.